You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News and reporting on prostate cancer.
The group now states that men with unfavorable intermediate-risk or high-risk disease can consider testing with Myriad's Prolaris or GenomeDx's Decipher.
The reimbursement contract provides about 9 million additional men access to the urine-based, genomic EPI test, Bio-Techne said.
If the results are validated, investigators believe the method could help diagnose patients without the need for a needle biopsy and with fewer false positives.
The Medicare Administrative Contractor is aligning its coverage decision with Palmetto GBA's final decision and it will go into effect May 4.
Called Proclarix, the test combines the levels of two proteins with free and total PSA and patient age to assess risk of clinically significant prostate cancer.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The system, called Galen Prostate, uses a proprietary algorithm to help pathologists detect and grade prostate cancer in biopsies.
Opko recorded $177.9 million in service revenues, $32 million in product revenues, and $14.4 million from licensing and the transfer of intellectual property revenues.
Billable test volume for the company's ConfirmMDx prostate cancer test fell 5 percent year over year, but global volume for its SelectMDx test rose 61 percent.
The company's approach involves using both fluorescence in situ hybridization and next-generation sequencing to provide clinicians with information.